Replies to post #323715 on Avid Bioservices Inc (CDMO)

[biopharm]

Hyeryun Choe knew exactly that the trouble began once PS flips...
And why has she not responded lately regarding the targeting of flipped PS, the 5 years is about up and again, all should email and ask Hyeryun Choe if the decision to shut down R&D at Peregrine or Avid Bioservices means she can't continue targeting flipped PS ?

.....especially now since we know for a fact C1Q is a major factor....and flipped PS must be targeted

Has Oncologie purposely kept PS Targeting / IP interested scientists and others away from being able to advance PS Targeting ?

If so....why would Peregrine / Avid new BODs ever allow an agreement where it only looks on the surface as they were looking to maximize shareholder value re: PS Targeting and all IP royalties ....when the deal structure may actually hinder the full FULL advancement of the IP?

Any shareholder should naturally be curious.....and yes, great for some pennies increase in pps, but what if PS Targeting was allowed to take over in a way that means many Big Pharma IP revenues become extinct overnight....I bet extreme measures would have been taken